Get the Stockscreener App
1.48
6.47%
0.09
After Hours:
1.48
Okyo Pharma Limited stock is traded at $1.48, with a volume of 16,422.
It is up +6.47% in the last 24 hours and up +30.99% over the past month.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$1.39
Open:
$1.4
24h Volume:
16,422
Relative Volume:
0.16
Market Cap:
$50.16M
Revenue:
-
Net Income/Loss:
$-13.27M
P/E Ratio:
-9.0244
EPS:
-0.164
Net Cash Flow:
$-7.70M
1W Performance:
+2.07%
1M Performance:
+30.99%
6M Performance:
+38.97%
1Y Performance:
-4.52%
1-Day Range:
$1.375
$1.4865
1-Week Range:
$1.32
$1.4967
52-Week Range:
$0.8075
$1.74
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.48 | 49.21M | 0 | -13.27M | -7.70M | -0.164 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Okyo Pharma Limited Stock (OKYO) Latest News
OKYO Pharma ("OKYO" or the "Company")announces issuance of U.S. Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain - Barchart.com
OKYO Pharma’s (OKYO) Buy Rating Reaffirmed at HC Wainwright - Defense World
Neuropathic Ocular Pain Market Expected to Experience Major - openPR.com
Neuropathic Ocular Pain Market Expected to Experience Major Growth by 2034, According to DelveInsight | Novartis, OKYO Pharma, AbbVie Inc., Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum - Barchart.com
Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com
OKYO Pharma Limited (NASDAQ:OKYO) Sees Significant Decrease in Short Interest - Defense World
ADS Program collapse - Investegate
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain - marketscreener.com
OKYO moves toward FDA talks after eye drug trial – ICYMI - Proactive financial news
FDA grants fast track to OKYO Pharma’s neuropathic pain drug - Investing.com Australia
Small cap wrap: GoviEx, NextSource Materials, Voyageur Pharmaceuticals, OKYO Pharma... - Proactive financial news
FDA grants fast track to OKYO Pharma’s neuropathic pain drug By Investing.com - Investing.com Nigeria
FDA grants fast track designation to OKYO Pharma’s urcosimod for treatment of neuropathic corneal pain - Ophthalmology Times
OKYO Pharma’s Urcosimod Receives FDA Fast Track Designation for Neuropathic Corneal Pain - TipRanks
FDA Fast-Tracks Novel Eye Pain Drug: OKYO's Urcosimod Targets Untreated Corneal Condition - Stock Titan
OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal pain - Proactive financial news
OKYO Pharma accelerates neuropathic corneal pain treatment with early closure of Phase 2 trial - Proactive financial news
Market movers: Snap, Super Micro Computer, OKYO Pharma... - Proactive financial news
Okyo Pharma announces plans to accelerate development of urcosimod - TipRanks
OKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal Pain - TipRanks
OKYO Pharma speeds up NCP drug development - Investing.com
OKYO Pharma Announces Plans to Accelerate the Clinical - GlobeNewswire
OKYO Pharma Limited Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain - marketscreener.com
OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal pain - Proactive financial news
Press Release Distribution & PR Platform - ACCESS Newswire
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - ADVFN
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain - ADVFN
Kyverna Therapeutics (NASDAQ:KYTX) and OKYO Pharma (NASDAQ:OKYO) Financial Review - Defense World
OKYO Pharma CEO discusses FDA Fast Track filing for urcosimodICYMI - Proactive financial news
OKYO Pharma achieves key stability milestone for Urcosimod in clinical development - Proactive financial news
OKYO Stock Price and Chart — NASDAQ:OKYO - TradingView
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod - GlobeNewswire
Small cap wrap: OKYO Pharma, Charbone Hydrogen, Hillcrest... - Proactive financial news
OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment - Seeking Alpha
OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain - Ophthalmology Times
Urcosimod shows promise in long-term stability test - Investing.com
OKYO Pharma confirms stability of drug candidate By Investing.com - Investing.com South Africa
Urcosimod shows promise in long-term stability test By Investing.com - Investing.com India
OKYO Pharma Achieves Key Stability Milestone for Urcosimod - TipRanks
OKYO Pharma confirms stability of drug candidate - Investing.com
OKYO Pharma reports long-term shelf stability of corneal pain treatment - Proactive financial news
Dauntless Investment Group, LLC Acquires Significant Stake in OK - GuruFocus
OKYO Pharma (NASDAQ:OKYO) versus IN8bio (NASDAQ:INAB) Head-To-Head Analysis - Defense World
OKYO Pharma Limited (NASDAQ:OKYO) Sees Significant Growth in Short Interest - Defense World
Okyo Pharma Limited Announces Filing of A Patent Application Covering the Use of Chemerin and Associated Analogues to Treat “Cytokine Storm” Associated with COVID-19 and ARDS - marketscreener.com
OKYO Pharma seeks FDA fast track for eye pain treatment By Investing.com - Investing.com Australia
OKYO Pharma seeks FDA Fast Track for eye pain drug By Investing.com - Investing.com Australia
OKYO Pharma seeks FDA fast track for eye pain treatment - Investing.com India
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):